Company intelligence / Profile preview

OncoQR ML

Ownership: Private
Development stage: Preclinical

Overview

OncoQR ML has demonstrated in vivo proof of concept for its lead candidates targeting G17 and HER2/neu. The S-TIR™ platform enables the activation of all four natural tumor-killing immune mechanisms in a tumor-specific manner. Lead programs have shown robust immune responses and preclinical efficacy in animal models; no clinical data reported yet.

Therapeutic areas: Oncology
Modalities: VaccineBiologic (platform-based cancer immunotherapy)
Industry: Biotech

Drug pipeline

3 assets

OQR400

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

TYG Oncology Ltd. (joint venture for hormone neutralization therapies and co-development of TYG100/OQR100)

Beyond the preview

Go deeper on OncoQR ML.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OncoQR ML.

Explore the full profile